Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Maurice Petitou

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Genes & Molecular Sequences

Carbohydrate Sequence

Concepts & Ideas

Phenomena

Living Beings

Rabbits

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
27
Herbert, Jean-Marc
25
Lormeau, JC
19
Duchaussoy, Philippe
17
Hérault, Jean-Pascal
13
Boneu, Bernard
13
Sinaÿ, Pierre
11
Driguez, Pierre-A
9
Bernat, André
9
Torri, Giangiacomo
8
Casu, Benito
8
Sizun, Philippe
7
Saivin, Sylvie
7
van Boeckel, Constant
6
Meuleman, Dirk
6
Dupouy, Dominique

Sign-in to see all Coauthors

Publications

TOP 3
Petitou Maurice; Nancy-Portebois Vanessa; Dubreucq Guy; Motte Vincent; Meuleman Dick; de Kort Martin; van Boeckel Constant A A; Vogel Gerard M T; Wisse Jeffry A J
From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Savi Pierre; Chong Beng H; Greinacher Andreas; Gruel Yves; Kelton John G; Warkentin Theodore E; Eichler Petra; Meuleman Dick; Petitou Maurice; Herault Jean-Pascal; Cariou Roger; Herbert Jean-Marc
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.
Olson Steven T; Swanson Richard; Raub-Segall Elke; Bedsted Tina; Sadri Morvardi; Petitou Maurice; Hérault Jean-Pascal; Herbert Jean-Marc; Björk Ingemar
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Maurice Petitou (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Petitou Maurice; Nancy-Portebois Vanessa; Dubreucq Guy; Motte Vincent; Meuleman Dick; de Kort Martin; van Boeckel Constant A A; Vogel Gerard M T; Wisse Jeffry A J
From heparin to EP217609: The long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Thrombosis and haemostasis 2009;102(5):804-10.
2005: Savi Pierre; Chong Beng H; Greinacher Andreas; Gruel Yves; Kelton John G; Warkentin Theodore E; Eichler Petra; Meuleman Dick; Petitou Maurice; Herault Jean-Pascal; Cariou Roger; Herbert Jean-Marc
Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin.
Blood 2005;105(1):139-44.
2004: Olson Steven T; Swanson Richard; Raub-Segall Elke; Bedsted Tina; Sadri Morvardi; Petitou Maurice; Hérault Jean-Pascal; Herbert Jean-Marc; Björk Ingemar
Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Thrombosis and haemostasis 2004;92(5):929-39.
2004: Dementiev Alexey; Petitou Maurice; Herbert Jean-Marc; Gettins Peter G W
The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity.
Nature structural & molecular biology 2004;11(9):863-7.
2004: Petitou Maurice; van Boeckel Constant A A
A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Angewandte Chemie (International ed. in English) 2004;43(24):3118-33.
2003: Dewerchin Mieke; Hérault Jean-Pascal; Wallays Goedele; Petitou Maurice; Schaeffer Paul; Millet Laurence; Weitz Jeffrey I; Moons Lieve; Collen Désiré; Carmeliet Peter; Herbert Jean-Marc
Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin.
Circulation research 2003;93(11):1120-6.
2003: Savi P; Pflieger A-M; Hérault J-P; Michaux C; Duchaussoy P; Petitou M; Herbert J-M
Comparative effects of two synthetic oligosaccharides on platelet activation induced by plasma from HIT patients.
Journal of thrombosis and haemostasis : JTH 2003;1(9):2008-13.
2003: Sisu Eugen; Tripathy Sasmita; Mallet Jean-M; Driguez Pierre-A; Hérault Jean-P; Sizun Philippe; Herbert Jean-M; Petitou Maurice; Sinay Pierre
Synthesis of new conformationally constrained pentasaccharides as molecular probes to investigate the biological activity of heparin.
Biochimie 2003;85(1-2):91-9.
2003: Petitou Maurice; Casu Benito; Lindahl Ulf
1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site.
Biochimie 2003;85(1-2):83-9.
2003: Petitou Maurice
[From heparin to synthetic antithrombotic oligosaccharides]
Bulletin de l'Académie nationale de médecine 2003;187(1):47-56; discussion 56-7.
2002: Hérault J P; Gaich C; Bono F; Driguez P A; Duchaussoy P; Petitou M; Herbert J M
The structure of synthetic oligosaccharides in relation to factor IXa inhibition.
Thrombosis and haemostasis 2002;88(3):432-5.
2002: Petitou Maurice; Duchaussoy Philippe; Herbert Jean-Marc; Duc Gérald; El Hajji Mohamed; Branellec Jean-François; Donat François; Necciari José; Cariou Roger; Bouthier Jean; Garrigou Eric
The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Seminars in thrombosis and hemostasis 2002;28(4):393-402.
2002: Hérault J P; Bernat A; Roye F; Michaux C; Schaeffer P; Bono F; Petitou M; Herbert J M
Pharmacokinetics of new synthetic heparin mimetics.
Thrombosis and haemostasis 2002;87(6):985-9.
2002: Dennissen Michel A B A; Jenniskens Guido J; Pieffers Martijn; Versteeg Elly M M; Petitou Maurice; Veerkamp Jacques H; van Kuppevelt Toin H
Large, tissue-regulated domain diversity of heparan sulfates demonstrated by phage display antibodies.
The Journal of biological chemistry 2002;277(13):10982-6.
2002: Bauer Kenneth A; Hawkins David W; Peters Paul C; Petitou Maurice; Herbert Jean-Marc; van Boeckel Constant A A; Meuleman Dirk G
Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
Cardiovascular drug reviews 2002;20(1):37-52.
2001: Das S K; Mallet J M; Esnault J; Driguez P A; Duchaussoy P; Sizun P; Herault J P; Herbert J M; Petitou M; Sinaÿ P
Synthesis of conformationally locked L-iduronic acid derivatives: direct evidence for a critical role of the skew-boat 2S0 conformer in the activation of antithrombin by heparin.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(22):4821-34.
2001: Hricovíni M; Guerrini M; Bisio A; Torri G; Petitou M; Casu B
Conformation of heparin pentasaccharide bound to antithrombin III.
The Biochemical journal 2001;359(Pt 2):265-72.
2001: Herbert J M; Hérault J P; Bernat A; Savi P; Schaeffer P; Driguez P A; Duchaussoy P; Petitou M
SR123781A, a synthetic heparin mimetic.
Thrombosis and haemostasis 2001;85(5):852-60.
2001: Petitou M; Imberty A; Duchaussoy P; Driguez P A; Ceccato M L; Gourvenec F; Sizun P; Hérault J P; Pérez S; Herbert J M
Experimental proof for the structure of a thrombin-inhibiting heparin molecule.
Chemistry (Weinheim an der Bergstrasse, Germany) 2001;7(4):858-73.
1999: Tabeur C; Mallet J M; Bono F; Herbert J M; Petitou M; Sinaÿ P
Oligosaccharides corresponding to the regular sequence of heparin: chemical synthesis and interaction with FGF-2.
Bioorganic & medicinal chemistry 1999;7(9):2003-12.
1999: Kovensky J; Duchaussoy P; Bono F; Salmivirta M; Sizun P; Herbert J M; Petitou M; Sinaÿ P
A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomers.
Bioorganic & medicinal chemistry 1999;7(8):1567-80.
1999: Petitou M; Hérault J P; Bernat A; Driguez P A; Duchaussoy P; Lormeau J C; Herbert J M
[New antithrombotic oligosaccharides]
Annales pharmaceutiques françaises 1999;57(3):232-9.
1999: Duchaussoy P; Jaurand G; Driguez P A; Lederman I; Ceccato M L; Gourvenec F; Strassel J M; Sizun P; Petitou M; Herbert J M
Assessment through chemical synthesis of the size of the heparin sequence involved in thrombin inhibition.
Carbohydrate research 1999;317(1-4):85-99.
1999: Duchaussoy P; Jaurand G; Driguez P A; Lederman I; Gourvenec F; Strassel J M; Sizun P; Petitou M; Herbert J M
Identification of a hexasaccharide sequence able to inhibit thrombin and suitable for 'polymerisation'.
Carbohydrate research 1999;317(1-4):63-84.
1999: Petitou M; Driguez P A; Duchaussoy P; Hérault J P; Lormeau J C; Herbert J M
Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics.
Bioorganic & medicinal chemistry letters 1999;9(8):1161-6.
1999: Petitou M; Duchaussoy P; Driguez P A; Hérault J P; Lormeau J C; Herbert J M
New synthetic heparin mimetics able to inhibit thrombin and factor Xa.
Bioorganic & medicinal chemistry letters 1999;9(8):1155-60.
1999: Petitou M; Hérault J P; Bernat A; Driguez P A; Duchaussoy P; Lormeau J C; Herbert J M
Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Nature 1999;398(6726):417-22.
1998: Petitou M; Hérault J P; Lormeau J C; Helmboldt A; Mallet J M; Sinaÿ P; Herbert J M
Introducing a C-interglycosidic bond in a biologically active pentasaccharide hardly affects its biological properties.
Bioorganic & medicinal chemistry 1998;6(9):1509-16.
1998: Desai U R; Petitou M; Björk I; Olson S T
Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites.
Biochemistry 1998;37(37):13033-41.
1998: Dreef-Tromp C M; Basten J E; Broekhoven M A; van Dinther T G; Petitou M; van Boeckel C A
Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
Bioorganic & medicinal chemistry letters 1998;8(16):2081-6.
1998: Lei P S; Duchaussoy P; Sizun P; Mallet J M; Petitou M; Sinaÿ P
Synthesis of a 3-deoxy-L-iduronic acid containing heparin pentasaccharide to probe the conformation of the antithrombin III binding sequence.
Bioorganic & medicinal chemistry 1998;6(8):1337-46.
1998: Herbert J M; Hérault J P; Bernat A; van Amsterdam R G; Lormeau J C; Petitou M; van Boeckel C; Hoffmann P; Meuleman D G
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Blood 1998;91(11):4197-205.
1998: Desai U R; Petitou M; Björk I; Olson S T
Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin.
The Journal of biological chemistry 1998;273(13):7478-87.
1997: Badorc A; Bordes M F; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand J P; Herbert J M
New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
Journal of medicinal chemistry 1997;40(21):3393-401.
1997: Cros S; Petitou M; Sizun P; Pérez S; Imberty A
Combined NMR and molecular modeling study of an iduronic acid-containing trisaccharide related to antithrombotic heparin fragments.
Bioorganic & medicinal chemistry 1997;5(7):1301-9.
1997: Hoffmann P; Bernat A; Dumas A; Petitou M; Hérault J P; Herbert J M
The synthetic pentasaccharide SR 90107A/Org 31540 does not release lipase activity into the plasma.
Thrombosis research 1997;86(4):325-32.
1997: Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel J M; Bârzu T; Crépon B; Hérault J P; Lormeau J C; Bernat A; Herbert J M
Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Journal of medicinal chemistry 1997;40(11):1600-7.
1997: Petitou M; Barzu T; Herault J P; Herbert J M
A unique trisaccharide sequence in heparin mediates the early step of antithrombin III activation.
Glycobiology 1997;7(3):323-7.
1996: Herbert J M; Hérault J P; Bernat A; van Amsterdam R G; Vogel G M; Lormeau J C; Petitou M; Meuleman D G
Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Circulation research 1996;79(3):590-600.
1996: Han Z C; Bellucci S; Shen Z X; Maffrand J P; Pascal M; Petitou M; Lormeau J; Caen J P
Glycosaminoglycans enhance megakaryocytopoiesis by modifying the activities of hematopoietic growth regulators.
Journal of cellular physiology 1996;168(1):97-104.
1996: Tabeur C; Machetto F; Mallet J M; Duchaussoy P; Petitou M; Sinaÿ P
L-iduronic acid derivatives as glycosyl donors.
Carbohydrate research 1996;281(2):253-76.
1995: Grootenhuis P D; Westerduin P; Meuleman D; Petitou M; van Boeckel C A
Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
Nature structural biology 1995;2(9):736-9.
1994: Shen Z X; Basara N; Xi X D; Caen J; Maffrand J P; Pascal M; Petitou M; Lormeau J C; Han Z C
Fraxiparin, a low-molecular-weight heparin, stimulates megakaryocytopoiesis in vitro and in vivo in mice.
British journal of haematology 1994;88(3):608-12.
1994: Carrie D; Caranobe C; Saivin S; Houin G; Petitou M; Lormeau J C; Van Boeckel C; Meuleman D; Boneu B
Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216.
Blood 1994;84(8):2571-7.
1994: Jaurand G; Tabeur C; Petitou M
Synthesis of the basic disaccharide unit of heparin.
Carbohydrate research 1994;255():295-301.
1993: Bârzu T; Level M; Petitou M; Lormeau J C; Choay J; Schols D; Baba M; Pauwels R; Witvrouw M; De Clercq E
Preparation and anti-HIV activity of O-acylated heparin and dermatan sulfate derivatives with low anticoagulant effect.
Journal of medicinal chemistry 1993;36(23):3546-55.
1993: Sie P; Dupouy D; Caranobe C; Petitou M; Boneu B
Antithrombotic properties of a dermatan sulfate hexadecasaccharide fractionated by affinity for heparin cofactor II.
Blood 1993;81(7):1771-7.
1992: Bârzu T; Desmoulière A; Herbert J M; Level M; Herault J P; Petitou M; Lormeau J C; Gabbiani G; Pascal M
O-acylated heparin derivatives with low anticoagulant activity decrease proliferation and increase alpha-smooth muscle actin expression in cultured arterial smooth muscle cells.
European journal of pharmacology 1992;219(2):225-33.
1992: Saivin S; Dol F; Caranobe C; Petitou M; Lormeau J C; Sie P; Houin G; Boneu B
Influence of molecular weight upon the anticoagulant and pharmacokinetic properties of dermatan sulfate in the rabbit.
Thrombosis research 1992;66(5):527-35.
1992: Saivin S; Caranobe C; Petitou M; Lormeau J C; Houin G; Boneu B
Pharmacodynamic properties of long lasting butyryl heparin derivatives in the rabbit.
Thrombosis and haemostasis 1992;67(5):550-5.
1992: Saivin S; Caranobe C; Petitou M; Sie P; Lormeau J C; Level M; Crepon B; Houin G; Boneu B
Antithrombotic activity, bleeding effect and pharmacodynamics of a succinyl derivative of dermatan sulphate in rabbits.
British journal of haematology 1992;80(4):509-13.
1992: Saivin S; Petitou M; Lormeau J C; Dupouy D; Sié P; Caranobe C; Houin G; Boneu B
Pharmacological properties of a low molecular weight butyryl heparin derivative (C4-CY 216) with long lasting effects.
Thrombosis and haemostasis 1992;67(3):346-51.
1992: Saivin S; Petitou M; Lormeau J C; Dupouy D; Sie P; Caranobe C; Houin G; Boneu B
Pharmacologic properties of an unfractionated heparin butyryl derivative with long-lasting effects.
The Journal of laboratory and clinical medicine 1992;119(2):189-96.
1992: Petitou M
Chemical synthesis and hemisynthesis in the field of glycosaminoglycans.
Advances in experimental medicine and biology 1992;313():21-30.
1990: Bossennec V; Petitou M; Perly B
1H-n.m.r. investigation of naturally occurring and chemically oversulphated dermatan sulphates. Identification of minor monosaccharide residues.
The Biochemical journal 1990;267(3):625-30.
1990: Ragazzi M; Ferro D R; Perly B; Sinaÿ P; Petitou M; Choay J
Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III.
Carbohydrate research 1990;195(2):169-85.
1990: Ferro D R; Provasoli A; Ragazzi M; Casu B; Torri G; Bossennec V; Perly B; Sinaÿ P; Petitou M; Choay J
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences.
Carbohydrate research 1990;195(2):157-67.
1990: Dol F; Petitou M; Lormeau J C; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
The Journal of laboratory and clinical medicine 1990;115(1):43-51.
1989: Marra A; Dong X; Petitou M; Sinay P
Synthesis of disaccharide fragments of dermatan sulfate.
Carbohydrate research 1989;195(1):39-50.
1989: Bârzu T; Lormeau J C; Petitou M; Michelson S; Choay J
Heparin-derived oligosaccharides: affinity for acidic fibroblast growth factor and effect on its growth-promoting activity for human endothelial cells.
Journal of cellular physiology 1989;140(3):538-48.
1989: Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
Folia haematologica (Leipzig, Germany : 1928) 1989;116(6):851-7.
1988: Dol F; Caranobe C; Dupouy D; Petitou M; Lormeau J C; Choay J; Sié P; Boneu B
Effects of increased sulfation of dermatan sulfate on its in vitro and in vivo pharmacological properties.
Thrombosis research 1988;52(2):153-64.
1988: Petitou M; Lormeau J C; Choay J
Interaction of heparin and antithrombin III. The role of O-sulfate groups.
European journal of biochemistry / FEBS 1988;176(3):637-40.
1988: Sié P; Petitou M; Lormeau J C; Dupouy D; Boneu B; Choay J
Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.
Biochimica et biophysica acta 1988;966(2):188-95.
1988: Petitou M; Duchaussoy P; Lederman I; Choay J; Sinaÿ P
Binding of heparin to antithrombin III: a chemical proof of the critical role played by a 3-sulfated 2-amino-2-deoxy-D-glucose residue.
Carbohydrate research 1988;179():163-72.
1988: Petitou M; Lormeau J C; Perly B; Berthault P; Bossennec V; Sié P; Choay J
Is there a unique sequence in heparin for interaction with heparin cofactor II? Structural and biological studies of heparin-derived oligosaccharides.
The Journal of biological chemistry 1988;263(18):8685-90.
1988: Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau J C; Sié P; Choay J; Boneu B
Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Thrombosis and haemostasis 1988;59(2):295-8.
1987: Petitou M; Duchaussoy P; Lederman I; Choay J; Jacquinet J C; Sinaÿ P; Torri G
Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III.
Carbohydrate research 1987;167():67-75.
1987: Barzu T; van Rijn J L; Petitou M; Tobelem G; Caen J P
Heparin degradation in the endothelial cells.
Thrombosis research 1987;47(5):601-9.
1987: Ragazzi M; Ferro D R; Perly B; Torri G; Casu B; Sinaÿ P; Petitou M; Choay J
Conformation of the pentasaccharide corresponding to the binding site of heparin to antithrombin-III.
Carbohydrate research 1987;165(1):c1-5.
1986: Caranobe C; Petitou M; Dupouy D; Gabaig A M; Sié P; Buchanan M R; Boneu B
Heparin fractions with high and low affinities to antithrombin III are cleared at different rates.
Thrombosis research 1986;43(6):635-41.
1986: Bârzu T; Van Rijn J L; Petitou M; Molho P; Tobelem G; Caen J P
Endothelial binding sites for heparin. Specificity and role in heparin neutralization.
The Biochemical journal 1986;238(3):847-54.
1986: Casu B; Choay J; Ferro D R; Gatti G; Jacquinet J C; Petitou M; Provasoli A; Ragazzi M; Sinay P; Torri G
Controversial glycosaminoglycan conformations.
Nature 1986;322(6076):215-6.
1986: Petitou M; Duchaussoy P; Lederman I; Choay J; Sinaÿ P; Jacquinet J C; Torri G
Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-D-glucopyranosyl)-(1-4 )-O-(beta-D-glucopyranosyluronic acid)-(1-4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glu copyranosyl)-(1-4)-O-(2-O-sulfo-alpha-L-idopyranosyluronic acid)-(1-4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III.
Carbohydrate research 1986;147(2):221-36.
1985: Bârzu T; Molho P; Tobelem G; Petitou M; Caen J
Binding and endocytosis of heparin by human endothelial cells in culture.
Biochimica et biophysica acta 1985;845(2):196-203.
1985: Torri G; Casu B; Gatti G; Petitou M; Choay J; Jacquinet J C; Sinaÿ P
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue.
Biochemical and biophysical research communications 1985;128(1):134-40.
1984: Bârzu T; Molho P; Tobelem G; Petitou M; Caen J P
Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.
Nouvelle revue française d'hématologie 1984;26(4):243-7.
1981: Casu B; Oreste P; Torri G; Zoppetti G; Choay J; Lormeau J C; Petitou M; Sinäy P
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.
The Biochemical journal 1981;197(3):599-609.
1980: Choay J; Lormeau J C; Petitou M; Sinay P; Casu B; Oreste P; Torri G; Gatti G
Anti-Xa active heparin oligosaccharides.
Thrombosis research 1980;18(3-4):573-8.

Sign-in to see more